RELAx试验:无ARDS患者限制性与开放性呼气末正压比较的研究方案
RELAx是一项在荷兰13个ICU开展的全国性多中心随机对照非劣效性试验,计划纳入980例预计24小时内不能拔管的无肺损伤成人机械通气患者。患者随机接受低PEEP(0-5 cm H2O)或高PEEP(8 cm H2O)通气,主要终点为第28天无呼吸机天数且存活,非劣效界值为0.5天。
要点
- 无肺损伤机械通气患者中,低PEEP(0-5 cm H2O)对比高PEEP(8 cm H2O)的非劣效性尚待验证。
- 主要终点为第28天无呼吸机天数且存活,非劣效界值为0.5天。
- 所有患者均采用低潮气量通气,计划纳入980例成人ICU患者。
核心结论
- RELAx试验旨在验证无肺损伤机械通气患者中低PEEP通气是否非劣效于高PEEP通气。
研究设计与样本
- 全国性多中心随机对照非劣效性试验,在荷兰13个ICU开展,计划纳入980例成人机械通气患者。
- 纳入标准为无肺损伤且预计24小时内不能拔管的成人ICU患者,所有患者均使用低潮气量通气。
关键数值与推荐
- 低PEEP组接受0至5 cm H2O之间尽可能低的PEEP,高PEEP组接受8 cm H2O的PEEP。
- 主要终点为第28天无呼吸机天数且存活,非劣效界值为组间差异0.5天。
- 次要终点包括住院时长、死亡率及肺部并发症(严重低氧血症、大面积肺不张、需补救治疗、肺炎、气胸及ARDS发生)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence for benefit of high positive end-expiratory pressure (PEEP) is largely lacking for invasively ventilated, critically ill patients with uninjured lungs. We hypothesize that ventilation with low PEEP is noninferior to ventilation with high PEEP with regard to the number of ventilator-free days and being alive at day 28 in this population. METHODS/DESIGN: The "REstricted versus Liberal positive end-expiratory pressure in patients without ARDS" trial (RELAx) is a national, multicenter, randomized controlled, noninferiority trial in adult intensive care unit (ICU) patients with uninjured lungs who are expected not to be extubated within 24 h. RELAx will run in 13 ICUs in the Netherlands to enroll 980 patients under invasive ventilation. In all patients, low tidal volumes are used. Patients assigned to ventilation with low PEEP will receive the lowest possible PEEP between 0 and 5 cm H2O, while patients assigned to ventilation with high PEEP will receive PEEP of 8 cm H2O. The primary endpoint is the number of ventilator-free days and being alive at day 28, a composite endpoint for liberation from the ventilator and mortality until day 28, with a noninferiority margin for a difference between groups of 0.5 days. Secondary endpoints are length of stay (LOS), mortality, and occurrence of pulmonary complications, including severe hypoxemia, major atelectasis, need for rescue therapies, pneumonia, pneumothorax, and development of acute respiratory distress syndrome (ARDS). Hemodynamic support and sedation needs will be collected and compared. DISCUSSION: RELAx will be the first sufficiently sized randomized controlled trial in invasively ventilated, critically ill patients with uninjured lungs using a clinically relevant and objective endpoint to determine whether invasive, low-tidal-volume ventilation with low PEEP is noninferior to ventilation with high PEEP. TRIAL REGISTRATION: ClinicalTrials.gov , ID: NCT03167580 . Registered on 23 May 2017.
引用
- Algera AG, Pisani L, Bergmans DCJ, et al. RELAx - REstricted versus Liberal positive end-expiratory pressure in patients without ARDS: protocol for a randomized controlled trial. Trials. 2018. PMID: 29739430. doi:10.1186/s13063-018-2640-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。